辅助生殖技术治疗与多发性硬化风险——一项丹麦队列研究
该登记库全国队列纳入1996至2018年丹麦辅助生殖技术治疗女性及同期自然受孕女性,随访至2021年3月10日。辅助生殖技术暴露与多发性硬化发病无关联(aHR=1.08;95%CI,0.93-1.25),倾向性评分匹配亚组分析结果一致。
要点
- 辅助生殖技术治疗女性与未暴露女性相比,多发性硬化发病风险无显著差异(aHR=1.08;95%CI,0.93-1.25)。
- 成功辅助生殖周期与失败周期相比,2年内多发性硬化风险无显著差异(aHR=1.01;95%CI,0.58-1.76)。
- 辅助生殖周期数增加与多发性硬化风险呈非显著趋势,但基于小样本。
核心结论
- 接受辅助生殖技术治疗的女性与未暴露于辅助生殖技术的女性相比,似乎并未增加多发性硬化的发病风险。
研究设计与样本
- 基于登记库的全国队列研究,纳入1996至2018年丹麦体外受精登记库中首次卵巢刺激周期(体外受精或卵胞浆内单精子注射)的女性,以及丹麦医疗出生登记库中首次分娩且受孕日期在1996至2018年的女性,随访至2021年3月10日。
- 共纳入585,716名女性,其中63,791名(11%)在研究期间至少启动过一个体外受精或卵胞浆内单精子注射周期;排除卵母细胞捐赠周期。
- 全队列中位随访时间为12.4年(Q1-Q3=6.6-18.1)。
主要发现
- 与未接受辅助生殖技术而受孕的女性相比,辅助生殖技术治疗女性年龄更大(31.8岁 vs 27.5岁),更常拥有大学学位(45% vs 36%),更常在队列入组前接受过体外受精或卵胞浆内单精子注射以外的其他生育治疗(26% vs 3%)。
- 辅助生殖技术暴露与非辅助生殖妊娠相比,新发多发性硬化无关联(aHR=1.08;95%CI,0.93-1.25)。
- 基于倾向性评分匹配亚组的意向性治疗分析证实了上述结果。
- 在辅助生殖技术治疗女性的亚组分析中,成功辅助生殖周期(妊娠)与失败周期(未妊娠)相比,辅助生殖周期启动后2年内多发性硬化风险未增加(aHR=1.01;95%CI,0.58-1.76)。
- 辅助生殖周期数增加与多发性硬化风险呈非显著增加趋势,但基于小样本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 辅助生殖周期数增加与多发性硬化风险的非显著趋势基于小样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the incidence of multiple sclerosis (MS) among women who had undergone assisted reproductive technology (ART) treatment with the women who had conceived a child without previous ART treatment. DESIGN: A register-based nationwide cohort study. PATIENT(S): Women with a first ovarian stimulation cycle before in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) (i.e., ART treatment) recorded in the Danish IVF register between 1996 and 2018; and women recorded in the Danish Medical Birth Register with the birth of their first child where date of conception is between 1996 and 2018. The cohort was observed until March 10, 2021. INTERVENTION(S): Mainly included IVF, ICSI, and fresh embryo transfer with hormone stimulation. MAIN OUTCOME MEASURES: A diagnosis of MS recorded in the Danish Multiple Sclerosis Registry. Crude and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were calculated. RESULTS: A total of 585,716 women were included in the cohort of which 63,791 (11%) were exposed to at least one initiated IVF or ICSI cycle during the study period. Cycles with oocyte donation were excluded. The median follow-up time for the entire cohort was 12.4 years (Q1-Q3= 6.6-18.1). Compared with women conceiving without previous ART, ART treated women were older (31.8 years vs. 27.5 years), more often had a university degree (45% vs. 36%), and more often had received other fertility treatments than IVF or ICSI before cohort entry (26% vs. 3%). We found no association between incident MS and exposure to ART compared with non-ART pregnancy (aHR=1.08; 95 % CI, 0.93-1.25). An analysis following intention-to-treat principle on a propensity score matched sub cohort confirmed our results. In subgroup analysis including all ART cycles among the ART treated women, we found no increased risk of MS within 2 years of ART cycle start for successful ART cycles (pregnancy) compared with failed ART cycles (no pregnancy) (aHR=1.01; 95% CI, 0.58-1.76). We found a non-significant trend toward increased risk of MS with increasing numbers of ART cycles although based on small numbers. CONCLUSION(S): Women treated with ART do not seem to be at increased risk of developing MS compared with the women not exposed to ART.
引用
- Kopp TI, Pinborg A, Glazer CH, et al. Assisted reproductive technology treatment and risk of multiple sclerosis - a Danish cohort study. Fertil Steril. 2022. PMID: 36572624. doi:10.1016/j.fertnstert.2022.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。